Blood Bank of Delmarva (BBD) recently signed a three-year purchase agreement with Cerus Corporation for the Intercept Blood System for platelets and plasma.
“The implementation of the Intercept system aligns with our mission of providing safe, effective blood products that best serve our hospital and patient community,” said BBD CEO Roy Roper. “We are excited to be one of the first centers to adopt pathogen inactivation as a proactive measure to mitigate the risk of transfusion-transmitted infections in our blood supply.”
BBD now provides blood transfusion products and services to hospitals and patients in the Delmarva region which includes Delaware; Cecil County, MD; and Maryland and Virginia’s Eastern shores. BBD supplies about 13,000 platelet and 21,000 plasma units each year.
The Intercept Blood System reduces the risk of transfusion-transmitted infections such as Hepatitis B and C, HIV, West Nile Virus and malaria that could be present in donated blood.
